Fig 1: Prognostic analysis of the identified proteins. Prognostic analysis of CD14 molecule (CD14), myeloperoxidase (MPO), neutrophil cytosolic factor 2 (NCF2), superoxide dismutase 2 (SOD2), poly(ADP-ribose) polymerase 1 (PARP1), methylmalonyl-CoA mutase (MUT), acyl-CoA dehydrogenase medium chain (ACADM) and phosphoenolpyruvate carboxykinase 1 (PCK1).
Fig 2: IHC results of the downregulated proteins in the RCC tumor samples. N, normal samples; T, tumor samples. IHC, immunohistochemistry; RCC, renal cell carcinoma. MUT, methylmalonyl-CoA mutase; ACADM, acyl-CoA dehydrogenase medium chain; PCK1, phosphoenolpyruvate carboxykinase 1.
Supplier Page from Abcam for Anti-Methylmalonyl Coenzyme A mutase antibody [EPR7738] - BSA and Azide free